Tandem Diabetes Care, Inc. announced that it has entered into a Settlement, Mutual Release and Cross-License Agreement with Roche. This agreement resolves all existing and potential patent disputes related to Tandem’s t:slim X2 insulin pump and two European Patents, EP 2 196 231 B1 and EP 1 970 677 B1. The settlement includes all pending patent infringement actions, revocation actions, counterclaims for revocation, and actions for declaration of non-infringement of patents.
As part of the settlement, Tandem Diabetes Care agreed to pay Roche $36 million. This payment concludes the litigation and provides clarity regarding the intellectual property landscape for the t:slim X2 pump in Europe. The resolution allows Tandem to avoid ongoing legal costs and potential future liabilities associated with the patent dispute.
This agreement is significant for Tandem as it removes a legal overhang and ensures continued market access for its t:slim X2 pump in regions covered by these European patents. The one-time payment impacts the company's financials but provides long-term operational certainty.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.